<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03495050</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00290-55</org_study_id>
    <nct_id>NCT03495050</nct_id>
  </id_info>
  <brief_title>BIVOLUTX: Bicuspid Aortic Stenosis With Evolut Platform International Experience.</brief_title>
  <acronym>BIVOLUTX</acronym>
  <official_title>BIVOLUTX: Bicuspid Aortic Stenosis With Evolut Platform International Experience.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Pasteur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Pasteur</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective non interventional, observational registry of 150 patients undergoing TAVI with
      Evolut platform for bicuspid aortic stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design Study Design: prospective non-interventional multicenter registry Screening:
      MSCT submitted to core lab &amp; sizing strategy pre-declared (annular sizing, supra-annular
      sizing, mix of both methods) Follow up: MSCT and TTE to cooper lab

      TAVI treatment Predilatation according to aortic annulus Dmin Evolut Pro (23-26-29) and
      Evolut R 34 XL Annular anchoring of the THV Postdilatation according to the operators'
      discretion Study Population All consecutive patients presenting with severe and symptomatic
      bicuspid aortic valve stenosis or mixed disease

      Inclusion Criteria 1. Age ≥18 years. 2. NYHA≥2 and/or syncope and/or angina. 3. Patient
      judged by the Heart Team as indicated for TAVI. 4. Anatomical suitability for
      transfemoral-TAVI with Evolut Pro or Evolut R XL, based on MSCT assessment.

      5. Estimated life-expectancy&gt;1 year.

      Exclusion Criteria 1. Age &lt;18 years 2. Asymptomatic patients 3. Estimated life expectancy&lt;1
      year 4. Pure aortic regurgitation. 5. LVEF&lt;20% 6. No baseline MSCT evaluation. 7. Unsuitable
      aortic root anatomy for Evolut Pro or XL. 8. Unsuitable peripheral vasculature for
      transfemoral Evolut Pro or XL. Primary Endpoint Valve performane Secondary endpoints 30 day
      and 1 year mortality Patient-prosthesis mismatch Ellipticity index at 30 days Follow-up 30
      days: physical examination, ECG, TTE /MSCT upon operators' judgement

      1 year: physical examination, ECG, TTE.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Valve performance</measure>
    <time_frame>30 days</time_frame>
    <description>effective orifice area&lt;0.85 cm2/m2 and/or mean gradient&gt;20 mmHg and/or aortic regurgitation&gt;moderate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Valve performance</measure>
    <time_frame>one year</time_frame>
    <description>effective orifice area&lt;0.85 cm2/m2 and/or mean gradient&gt;20 mmHg and/or aortic regurgitation&gt;moderate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>30 days and one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-prosthesis mismatch</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>indexed effective area &lt;0.65 cm2/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ellipticity index at 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Bicuspid Aortic Valve</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation</intervention_name>
    <description>Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform</description>
    <other_name>Transcatheter Aortic Valve Replacement</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients presenting with severe and symptomatic bicuspid aortic valve
        stenosis or mixed disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years.

          2. NYHA≥2 and/or syncope and/or angina.

          3. Patient judged by the Heart Team as indicated for TAVI.

          4. Anatomical suitability for transfemoral-TAVI with Evolut Pro or Evolut R XL, based on
             MSCT assessment.

          5. Estimated life-expectancy&gt;1 year.

        Exclusion Criteria:

          1. Age &lt;18 years

          2. Asymptomatic patients

          3. Estimated life expectancy&lt;1 year

          4. Pure aortic regurgitation.

          5. LVEF&lt;20%

          6. No baseline MSCT evaluation.

          7. Unsuitable aortic root anatomy for Evolut Pro or XL.

          8. Unsuitable peripheral vasculature for transfemoral Evolut Pro or XL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Didier TCHETCHE, MD</last_name>
    <phone>33562211699</phone>
    <email>d.tchetche@clinique-pasteur.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Didier TCHETCHE, MD</last_name>
    <email>d.tchetche@clinique-pasteur.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <state>Occitanie</state>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier TCHETCHE, MD</last_name>
      <phone>33562211699</phone>
      <email>d.tchetche@clinique-pasteur.com</email>
    </contact>
    <contact_backup>
      <last_name>Didier TCHETCEH, MD</last_name>
      <phone>33562211699</phone>
      <email>d.tchetche@clinique-pasteur.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>June 10, 2018</last_update_submitted>
  <last_update_submitted_qc>June 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Pasteur</investigator_affiliation>
    <investigator_full_name>Didier TCHETCHE</investigator_full_name>
    <investigator_title>Head of structural heart disease program</investigator_title>
  </responsible_party>
  <keyword>Bicuspid</keyword>
  <keyword>TAVI</keyword>
  <keyword>TAVR</keyword>
  <keyword>self-expanding</keyword>
  <keyword>Evolut</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Mutual ananymized database. Substudies anticipated.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

